BUILDING TOMORROW, TOGETHER

Kimball® Electronics

Fourth Quarter Fiscal 2026 Results

Quarter Ended June 30, 2026

Supplementary Information to the August 13, 2026, Earnings Conference Call & Webcast

Safe Harbor Statement

Certain statements contained within this supplementary information, including our fiscal year 2027 guidance, and any statements made during our earnings conference call today may be considered forward-looking under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as "expect," "should," "goal," "predict," "will," "future," "optimistic," "confident," and "believe." Undue reliance should not be placed on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These forward-looking statements are subject to risks and uncertainties including, without limitation, global economic conditions, geopolitical environment and conflicts such as war, global health emergencies, availability or cost of raw materials and components, tariffs and other trade barriers, foreign exchange rate fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of Kimball Electronics, Inc. (the "Company") are contained in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2025, our earnings release, and other filings with the Securities and Exchange Commission (the "SEC").

This supplementary information contains non-GAAP financial measures. The non-GAAP financial measures contained herein include Constant Currency Growth, Adjusted Selling & Administrative Expenses, Adjusted Operating Income, Adjusted EBITDA Adjusted Net Income, Adjusted Diluted Earnings Per Share, and Normalized Sales Growth. Management believes these measures are useful and allow investors to meaningfully trend, analyze, and benchmark the performance of the Company's core operations. Many of the Company's internal performance measures that management uses to make certain operating decisions use these and other non-GAAP measures to enable meaningful trending of core operating metrics. Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included on the Reconciliation of Non-GAAP Results slide, which is in the Appendix of this supplementary information.

Today's speakers

Ric Phillips
CEO

Jana Croom
CFO

- Opening comments
- Financial results for the quarter
- Guidance for fiscal 2027
- Closing comments
- Q&A

Kimball Electronics

Proud of fourth quarter results and good finish to the fiscal year

- Sales in Q4 were in line with expectations
- Adjusted Operating Income exceeded estimates
- Strong cash from operations used to paydown debt
  - Lowest debt levels in over 4 years
- Balance sheet continued to strengthen… actively leveraging it to make strategic investments in growth, such as:
  - Buildout of our new medical facility in Indianapolis
  - The acquisition of Helvoet Polymer Technologies

Guidance for fiscal 2027 highlights

- Highlighted by organic sales growth
- The accretive impact from Helvoet
- Expect Medical to continue to outpace the other two verticals
- Represent more than one-third of total Company sales in the fiscal year
- In line with our objectives to balance the portfolio across the markets we serve

$372M Net Sales





- Decline of (2%) compared to Q4 last year
- Sequential increase of 5%, experiencing growth in all three verticals compared to Q3
- Geographically, sales in the fourth quarter were more evenly distributed around the world versus prior periods

* Percentage decrease compared to Q4 of fiscal 2025

$109M

Medical Net Sales



- Sleep Therapy and Respiratory Care
- AED
- Surgical Devices
- In Vitro Diagnostics
- Image Guided Therapy
- Drug Delivery/Autoinjectors
- Patient Monitoring
- Blood Separation

- Growth year-over-year and compared to Q3
- Completing a fiscal year:
  - With year-over-year growth in all 4 quarters
  - Total Growth exceeded +10%***
- ~30% of these sales occurred in both Asia and Europe, with the same year-over-year increases in each region
- North America was down mid-single digits
- Product growth was driven by demand for:
  - Surgical Devices
  - Invitro Diagnostics
  - Patient Monitoring
  - Drug Delivery

* Percentage of sales

** Percentage increase compared to Q4 of fiscal 2025

*** Normalizing large one-time inventory consignment in prior year of $24M

Kimball Electronics

Automotive Net Sales

$170M

Automotive (3%)**



- Electronic Power Steering
- Electronic Braking Systems
- Body Controls

- Down (3%) compared to same period LY
- 46% of total
- Q4 revenue roughly divided in thirds:
  - Poland & Romania up mid-single digits
  - China increased low-single digits
  - North America offsetting increases
- Steering programs continue to account for ~70% of Automotive sales
- Fiscal 2026 down 7%... declines in back half of year suggest stabilizing trend

* Percentage of sales
** Percentage decrease compared to Q4 of fiscal 2025

Kimball Electronics

$93M Industrial Net Sales

Industrial (5%)**



- Climate Controls
- Public Safety
- Smart Metering
- Off Highway Equipment/Commercial Transportation
- IoT and Factory Automation
- Efficient Energy
- Automation Controls

- Decreased (5%) compared to Q4 last year
- 25% of total
- Industrial business heavily concentrated in North America
  - Majority of the decline due to lower demand for HVAC systems
- Partially offset by higher sales in smart meters in Europe
  - Continues to recover from prior year declines

* Percentage of sales

** Percentage decrease compared to Q4 of fiscal 2025

Net sales in the fourth quarter were $371.6 million

- (2%) decrease year-over-year
- Foreign exchange +1% favorable impact



Gross margin rate in the fourth quarter was 8.9%

- Improvement of +90 bps compared to 8.0% in Q4 of fiscal year 2025
- Favorable mix
- Partially offset by incremental costs associated with the ramp-up of our medical CDMO facility in Indianapolis



Adjusted selling & administrative expense (1)

- Fourth quarter $14.8 million, increase of $4 million year-over-year
- Higher expenses from investments in future growth initiatives
  - Personnel costs
  - IT infrastructure
- When measured as percent of sales the rate was 4.0% this year compared to 2.8% same period last year



(1) Adjusted Selling & Administrative Expense is a Non-GAAP measure – refer to Reconciliation of Non-GAAP Results in the supplementary information.

Adjusted operating income in the fourth quarter (1)

- $18.1 million, or 4.9% of net sales
- Compares to last year's adjusted result of $19.6 million, or 5.2% of net sales



(1) Adjusted Operating Income is a Non-GAAP measure – refer to Reconciliation of Non-GAAP Results in the supplementary information.

Other income / expense

- Expense of $2.6 million, compared to $3.8 million of expense last year
- Interest expense drove the decrease, down nearly 30% year-over-year
  - Lower average debt levels
  - Lower borrowing rates

Effective tax rate

- ETR in Q4 was 67.8% compared to 48.3% last year
- Rate this quarter impacted by the resolution of two long-standing dividend withholding matters with tax authorities at international locations
- Ended the fiscal year at 47.5%
- Expecting the rate in fiscal 2027 to be in the low 30%'s

Adjusted Net Income and Adjusted Diluted EPS (1)



(1) Adjusted Net Income and Adjusted Diluted EPS are Non-GAAP measures – refer to Reconciliation of Non-GAAP Results in the supplementary information.

Turning to the balance sheet…

- Cash and cash equivalents at June 30, 2026, were $88.9 million
- Cash generated by operating activities in the quarter was a robust $42.4 million
  - Tenth consecutive quarter of positive cash flow
- Cash conversion days were 82, 8-day improvement compared to last quarter, and a 3-days improvement compared to Q4 of fiscal 2025
  - Best CCD in 17 quarters, with all components posting good results

Inventory ended the quarter at $271.9 million… down slightly

- $1.4 million decline compared to Q3
- $1.6 million lower than a year ago



Capital expenditures in Q4 were $8.5 million (1)

- Leasehold improvements in the new facility in Indianapolis
- Investments to support new programs in Europe
- Full year of fiscal 2026:
  - Invested $51.7 million in capex
  - In line with our estimates



(1) Capital Expenditures include purchases of capitalized software.

Kimball Electronics

Borrowings were $116.6 million… the lowest level of debt in 4+ years

- Decrease of $46.4 million from the third quarter
- Down $30.9 million, or ~21%, from a year ago
- Short-term liquidity totaled $411.3 million at the end of the fourth quarter



Reminder: Acquisition of Helvoet occurred on July 1st – the beginning of fiscal 2027

Share repurchases

- Invested $2.1 million to repurchase 83,000 shares
- Since October 2015, under our Board authorized share repurchase program:
  - A total of $115.6 million returned to Share Owners by repurchasing 7.1 million shares of common stock
  - In May, our Board of Directors unanimously increased the share repurchase program by $20 million
  - We now have $24.4 million available on the program

As we expected, fiscal 2026 was a year of transition…

- Net sales of $1.431 billion
    - Medical end-market vertical up over 10%, after normalizing last year for a consigned inventory sales
- Adjusted operating income was $65.7 million, or 4.6% of net sales
- Cash generated from operating activities was $72.3 million
- Invested $11.9 million to repurchase 447,000 shares of common stock

CFO who takes great pride in the condition of the balance sheet

- Exited fiscal year in a position of strength
- Plenty of dry powder in the form of borrowing capacity and available cash to strategically invest
- Guidance for fiscal 2027 projects a return to growth
- We will be leveraging the balance sheet to support those efforts

Guidance for fiscal 2027

FY27 Guidance	
Sales	$1.535 -$1.560 *billion*
Adjusted OI%	4.4% - 4.7% *of net sales*
CapEx	$50 - $60 *million*

- Sales growth of 7% - 9%
- Organic sales growth of 3% - 5%
  - Medical in the high single digit to low double-digit range
  - Industrial in line with Company average
  - Automotive flattish
- Helvoet sales of $60 million

Closing thoughts…

- Base business stabilizing, returning to organic sales growth
- Medical vertical will approach 35% of the total Company in fiscal 2027
- Helvoet is an important contributor
  - Since announcement in July, integration efforts have gone very well
  - Number one priority is unlocking top line synergies
  - Customer interest has been strong… requests for more information
- Good progress moving into new facility in Indianapolis
  - Production equipment being installed… qualification starts in Fall
  - Early production at the end of the calendar year

How we talk about our Medical business…

- Co-development work done by both Kimball and Helvoet
- Now incorporating “D” in our reference to the Medical CDMO business
- Reflective of our go-to-market strategy as a full-service provider in Kimball Solutions

Looking ahead…

- Evaluate strategic opportunities, potentially accelerating the expansion of our medical CDMO business
  - “Lift & shift” of an active program
  - Production of new medical products
  - Possible future inorganic growth… overtime
- Helvoet adds to this strategy:
  - Expertise in precision manufacturing and automation
  - Exposure to highly attractive medical end-markets
  - Presence or expanded presence in a new geography
  - Well-run operation with an excellent management team

For more information, please contact…

Andy Regrut

Vice President, Investor Relations, Strategic Development, and Treasurer

812–827–4151

andy.regrut@kimballelectronics.com

Appendix

Reconciliation of non-GAAP results

(Unaudited, Amounts in Thousands, Except Per Share Data)	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26
Net Sales Growth (vs. same quarter in prior year)	(12)%	(2)%	(5)%	(6)%	(2)%
Foreign Currency Exchange Impact	1 %	1 %	2 %	3 %	1 %
Constant Currency Growth	(13)%	(3)%	(7)%	(9)%	(3)%
Selling & Administrative Expenses, as reported	$ 13,163	$ 13,090	$ 14,862	$ 15,214	$ 17,989
Less: Stock Compensation Expense	1,991	1,563	2,217	2,256	2,196
Less: SERP	329	225	85	(76)	432
Less: Acquisition Costs	—	—	—	—	524
Adjusted S&A Expense	$ 10,843	$ 11,302	$ 12,560	$ 13,034	$ 14,837
Operating Income, as reported	$ 16,474	$ 14,454	$ 10,767	$ 11,755	$ 29,081
Add: Stock Compensation Expense	1,991	1,563	2,217	2,256	2,196
Add: SERP	329	225	85	(76)	432
Add: Restructuring Expense	1,971	1,416	1,817	850	894
Add: Asset Impairment (Gain on Disposal)	(1,127)	(124)	422	(4)	(15,015)
Add: Acquisition Costs	—	—	—	—	524
Adjusted Operating Income	$ 19,638	$ 17,534	$ 15,308	$ 14,781	$ 18,112
Adjusted Operating Income	$ 19,638	$ 17,534	$ 15,308	$ 14,781	$ 18,112
Depreciation & Amortization	9,582	9,117	9,252	10,295	10,041
Adjusted EBITDA	$ 29,220	$ 26,651	$ 24,560	$ 25,076	$ 28,153
Net Income, as reported	$ 6,581	$ 10,086	$ 3,637	$ 5,719	$ 8,518
Add: Stock Compensation Expense, After-Tax	1,510	1,185	1,681	1,711	1,665
Add: Restructuring Expense, After-Tax	1,474	1,073	1,287	606	644
Add: Asset Impairment (Gain on Disposal), After-Tax	(1,127)	(94)	320	(3)	(11,387)
Add: Acquisition Costs, After-Tax	—	—	—	—	397
Adjusted Net Income	$ 8,438	$ 12,250	$ 6,925	$ 8,033	$ (163)
Diluted Earnings per Share, as reported	$ 0.26	$ 0.40	$ 0.15	$ 0.23	$ 0.35
Add: Stock Compensation Expense	$ 0.06	$ 0.05	$ 0.07	$ 0.07	$ 0.07
Add:Restructuring Expense	$ 0.06	$ 0.04	$ 0.05	$ 0.03	$ 0.03
Add: Asset Impairment (Gain on Disposal)	$ (0.04)	$ —	$ 0.01	$ —	$ (0.47)
Add: Acquisition Costs	$ —	$ —	$ —	$ —	$ 0.01
Adjusted Diluted Earnings per Share	$ 0.34	$ 0.49	$ 0.28	$ 0.33	$ (0.01)

Kimball Electronics

Reconciliation of non-GAAP results continued…

	Three Months Ended March 31, 2026	Twelve Months Ended June 30, 2026
Net Sales Growth (vs. same period in prior year), Consolidated	(6)%	(4)%
Impact of Non-recurring Consignment Inventory Sales (1)	7%	2%
Normalized Sales Growth, Consolidated	1%	(2)%
Net Sales Growth (vs. same period in prior year), Medical	(8)%	4%
Impact of Non-recurring Consignment Inventory Sales (1)	25%	7%
Normalized Sales Growth, Medical	17%	11%

(1) Q3’25 included a non-recurring consignment inventory sale of $24 million to a customer for completed programs.

Net Sales Mix by Market Vertical(1)



(1) Beginning in the first quarter of fiscal year 2026, sales to customers related to commercial transportation, previously included in the automotive vertical, are now reflected in the industrial vertical. Prior periods have been recast to conform to current period presentation.

Net sales in Automotive (1)



(1) Beginning in the first quarter of fiscal year 2026, sales to customers related to commercial transportation, previously included in the automotive vertical, are now reflected in the industrial vertical. Prior periods have been recast to conform to current period presentation.

Net sales in Medical

Net sales in Industrial (1)

(1) Beginning in the first quarter of fiscal year 2026, sales to customers related to commercial transportation, previously included in the automotive vertical, are now reflected in the industrial vertical. Prior periods have been recast to conform to current period presentation.

Adjusted EBITDA(1)



(1) Adjusted EBITDA is a Non-GAAP measure - refer to Reconciliation of Non-GAAP Results in the supplementary information.

Operating cash flow